Benjamin Graham Detailed Fundamental Analysis

Regeneron Pharmaceuticals (REGN) was assessed by Validea's Benjamin Graham Value Investor model, scoring 71%. Although the biotechnology firm passed criteria for sales, debt, and long-term EPS growth, it notably failed the critical low P/E and Price/Book ratio tests, indicating it does not meet the model's deep value investment thresholds.

Analysis

Regeneron Pharmaceuticals (REGN) presents a mixed profile according to Validea's Benjamin Graham-based value investing model, scoring a moderate 71%. The analysis indicates the company possesses strong underlying fundamentals, successfully passing criteria for sales performance, a healthy current ratio, low long-term debt relative to net current assets, and solid long-term EPS growth. However, REGN fails to meet the model's core valuation tests, specifically on its Price-to-Earnings (P/E) and Price-to-Book (P/B) ratios. This suggests that while the large-cap biotechnology firm is financially robust and growing, its current market price is too high to be considered a 'deep value' opportunity under the strict Graham framework, which requires a significant margin of safety. The 71% score falls below the 80% threshold that typically signals notable interest from this specific strategy.

Key Decisions for Investors

• Strict value investors following a Graham-style discipline should note that REGN does not currently meet the required valuation criteria, as its P/E and P/B ratios are elevated.
• Investors with a 'Growth at a Reasonable Price' (GARP) or growth-focused strategy could interpret the strong fundamental signals—including sales and EPS growth with low debt—as a positive, warranting a closer look to justify the premium valuation.
• Consider monitoring REGN for potential price pullbacks, as a significant decline could bring its valuation metrics into a range that aligns with value-based models, presenting a more attractive entry point.